ClinicalTrials.gg
RecruitingNCT03889743INSTARUpdated Jul 20, 2026

Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing

A Phase 4 interventional study of Dexamethasone treatment during 3 days and placebo treatment during 3 days in Asthma and Inflammation, sponsored by St. Olavs Hospital. Recruiting at 8 sites in 3 countries. Open to participants aged 3 Months to 23 Months. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by St. Olavs Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
3 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Asthma with a site in Norway — 2 open to participants now, 3 under way, none of them phase 3. Asthma · Norway.

Planned enrollment
14th of 23
280 · median 318
Started
2019
the only one that year
Phase 4
5 of 30
1 open now
Registered
23rd of 30
by date
Lead sponsor
3 of 30
St. Olavs Hospital

Among the 30 studies in Asthma with a site in Norway, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 4, and was the 23rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 30 studies in Asthma with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 3 Months to 23 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Asthma with a site in Norway, or all of them as a file.
02

Study summary

The overall objective of the study is to determine the efficacy of corticosteroids in preventing recurrent wheezing and asthma in high-risk, first-time severe wheezing children with rhinovirus infection, stratified by rhinovirus genome load.

The secondary objectives are to determine duration and severity of each acute episode with acute expiratory breathing difficulty, the number of episodes with acute expiratory breathing difficulty, degree of pulmonary hyperreactivity and quality of life within 24 months after study entry.

Read the detailed description

Asthma is a major and growing public health problem in Norway and beyond. The reason for the increased occurrence of asthma is still poorly understood. However, the disease is a result of a complex interplay between genetic and environmental factors. The current view of asthma pathogenesis is that an abnormal immune response to environmental agents, such as allergens or respiratory viruses, is responsible for initiation and perpetuation of chronic inflammation in genetically susceptible individuals. It is also increasingly evident that asthma originates early in life. However, intervention measures introduced before birth and during the first year of life that reduced or eliminated exposure to house dust, pets, and tobacco smoke together with encouragement of breast-feeding and delayed introduction of solid foods, only had minor effects in preventing asthma development. Thus, there is an urgent need to develop new approaches to asthma prevention in young children.

Recent evidence suggests that rhinovirus infection is a main and independent trigger of acute wheezing and asthma exacerbations in children. Rhinovirus may cause 20-40% of acute wheezing episodes (bronchiolitis) in children during the first 2 years of life, and up to 90% of asthma exacerbations in older children. Rhinovirus etiology of early wheezing is particularly interesting because it has been strongly associated with recurrent wheezing and doctor-diagnosed asthma up to 13 years of age. The strength of this effect has been reported with odds ratios ranging from 3 to 10 during early life. Previously, personal objective markers for increased asthma risk have mainly been related to the presence of atopy development, but atopic disease with eczema generally manifests later, at age 2-3 years. This understanding of early-life rhinovirus associated wheezing as an early marker for asthma has opened a novel opportunity for effective secondary prevention of asthma by identifying children with increased risk of asthma.

Recognizing the role of rhinovirus as an early risk factor for asthma development, has made it essential to control viral effects. Unfortunately, no feasible rhinovirus antivirals are available for children yet.

Rhinovirus infection may lead to broken epithelial barriers facilitating development of inflammation, and asthma is a chronic inflammatory disease of the airways. It is becoming increasingly clear that control of early virus induced inflammation that may develop into chronic inflammation is crucial to intervene with the asthma disease development.

Most cases with bronchiolitis are caused by respiratory syncytial virus (RSV) and rhinovirus. Recent data have shown that RSV is associated with a more severe short-term outcome than rhinovirus, whereas rhinovirus more often than RSV is associated with a more severe long-term outcome related to atopic predisposition and with increased risk of developing asthma. In line with this, several randomized clinical trials (RCT) have failed to show any corticosteroid effect in preventing asthma after early-life infection with RSV. In contrast, and as a major finding that in fact have led to this project, researchers in Turku, Finland have previously reported a post hoc analysis of RCT data showing that a short treatment with oral prednisolone during the first wheezing episode caused by rhinovirus, reduced the risk of recurrent wheezing over the next 1 - 7 years. Moreover, in a prospective single-center RCT, the same researchers confirmed that children with high rhinovirus genome load did benefit from systemic corticosteroids by having fewer recurrences during a 12-month follow-up period and 25% less asthma diagnoses during a 1- and 4-year follow-up.16;17 Hence, asthma after RSV may not be prevented by corticosteroids because RSV infected children less often are atopic and less often develop chronic inflammation, whereas early rhinovirus induced wheezing often occur in genetic predisposed and/or atopic children, and therefore asthma development may be prevented by early corticosteroid intervention. These highly clinically relevant findings must be confirmed in an adequately powered multicenter RCT to fully address the clinical significance of corticosteroid intervention. We expect that this trial will be a landmark in demonstrating long-term disease modifying effects of recurrent wheezing and asthma inception.

03

Conditions studied

  • Asthma
  • Inflammation

Keywords

  • Respiratory Sounds
  • Steroids
  • Rhinovirus
04

Who can participate

Ages eligible
3 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • admitted to pediatric acute wards in the participating hospitals in Norway, Finland, Sweden.
  • referred for first severe wheezing episode, defined as first-time acute breathing difficulty with wheezing ever, appearing less than 7 days from onset of symptoms
  • one or more of the following:(a) fever, (b) hypoxia (SAT O2 \<= 92%), (c) retractions (inter-, subcostal), (d) prolonged expiration (on auscultation), (e) expiratory rhonchi (on auscultation)
  • evidence of rhinovirus infection by PCR-test in nasopharyngeal secretions
  • signed and expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to ICH GCP, and national/local regulations.

Exclusion criteria

Exclusion Criteria:

  • previous episodes with wheezing, defined as a history of acute breathing difficulty with wheezing in need of treatment at a general practitioner or at hospital, or parental information about similar breathing difficulties
  • gestational age \<37 weeks
  • chronic illness other than atopy (eczema),
  • previous systemic or inhaled treatment,
  • participation to another trial,
  • varicella infection or contact during the last 2-3 weeks,
  • need for intensive care unit treatment during the present infection, except for respiratory support with non-invasive methods (high flow nasal cannula ventilation, CPAP or BiPAP),
  • any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).
  • COVID-19 related disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Dexamethasone

    Drug: Dexamethasone treatment during 3 days

  • Placebo comparator
    controls

    Drug: placebo treatment during 3 days

Interventions

  • DrugDexamethasone treatment during 3 days

    Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.

  • Drugplacebo treatment during 3 days

    1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.

    Also known as: lactose

06

What researchers measure

Primary outcomes

  1. time to a new physician-confirmed wheezy episode within 24 months after study entry

    Time frame: 24 months

  2. time to need for a regular controller medication for asthma within 24 months after study entry

    Time frame: 24 months

Secondary outcomes

  1. duration of respiratory symptoms

    as determined at the first episode of acute breathing difficulty within 24 months of study entry

    Time frame: 24 months

  2. severity of respiratory symptoms

    as determined at the first episode of acute breathing difficulty within 24 months of study entry

    Time frame: 24 months

  3. the number of episodes with acute breathing difficulty since start of study medication

    as determined at scheduled follow-up visit within 24 months of study entry

    Time frame: 24 months

  4. the duration of episodes with acute breathing difficulty since start of study medication

    as determined at scheduled follow-up visit within 24 months of study entry

    Time frame: 24 months

  5. the degree of pulmonary hyperreactivity

    as determined at scheduled follow-up visit within 24 months of study entry

    Time frame: 24 months

  6. quality of life: Infant Toddler Quality of Life© (ITQOL©) questionnaire

    as determined at scheduled follow-up visit within 24 months of study entry

    Time frame: 24 months

  7. body height

    Time frame: 24 months

  8. body weight

    Time frame: 24 months

07

Study locations

8 of 8 sites recruiting
08

References and documents

Publications

  • Elvebakk T, Dollner H, Partty A, Jartti H, Vuorinen T, Oymar K, Nerheim S, Moe N, Nordbo SA, Follestad T, Koski J, Vollsaeter M, Hofstad A, Klingenberg C, Leknessund CB, Skjerven HO, Risnes K, Soderhall C, Sissener E, Inchley CS, Konradsen JR, Jartti T. INnovative Steroid Treatment to reduce Asthma development in children after first-time Rhinovirus-induced wheezing (INSTAR): protocol for a randomised placebo-controlled trial. BMJ Open. 2025 Jul 30;15(7):e103530. doi: 10.1136/bmjopen-2025-103530. PubMed 40738645 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for May 2028, 108 months after the start.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 108 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2019
First posted
Mar 26, 2019
StartActual
May 8, 2019
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03889743
Lead sponsor
St. Olavs Hospital
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
May 8, 2019
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 20, 2026

Study contacts

Henrik Døllner, md phd
Contact
henrik.dollner@ntnu.no
0047 73559531
Geir Bråthen
study director · St. Olavs Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion